A 22‐year single institution review of 119 cases of salivary duct carcinoma
Ethan J. Han,Laith A. Mukdad,Yazeed Alhiyari,Morcos N. Nakhla,Dipti P. Sajed,Maie A. St. John
DOI: https://doi.org/10.1002/lio2.1234
IF: 2.542
2024-03-23
Laryngoscope Investigative Otolaryngology
Abstract:Abstract Objective Salivary duct carcinoma (SDC) is a rare and aggressive salivary gland malignancy. Herein, we present the largest single‐institution review of SDC to date. Methods This is a retrospective cohort study of all histologically confirmed cases of SDC seen at our institution from January 1, 2002, to August 1, 2022. Patient demographics, treatment, histological characteristics, tumor staging, and outcomes were extracted from the electronic medical record. Kaplan‐Meier and Cox regression survival analyses were performed. Results This study included 119 patients with a mean age of 66.2 years. Most primary tumors arose from the parotid gland (72.3%), and 23.5% were noted to be carcinoma ex‐pleomorphic adenoma. 57.1% of patients presented with regional lymph node metastasis, whereas 23.5% presented with distant disease. Kaplan–Meier analysis demonstrated a 62.4% 5‐year overall survival (OS) and a 69.0% 5‐year disease‐specific survival (DSS). Univariate analyses indicated that presence of regional lymph node disease ( p <.001), distant metastasis ( p <.001), perineural invasion ( p = .027), and lymphovascular invasion ( p = .018) were predictive of decreased OS and DSS. Trastuzumab administration was not associated with survival in HER‐2‐positive patients receiving chemotherapy. Multivariate analyses demonstrated that presence of nodal disease (HR 30.337, 95% CI 2.782–330.851, p = .005) and carcinoma ex pleomorphic adenoma (HR 5.54, 95% CI 1.024–29.933, p = .047) were associated with decreased OS. Conclusion Our patients had more favorable survival rates compared to prior studies, which may be due to lower incidence of nodal disease. Factors associated with worse survival included nodal and distant metastases, perineural invasion, lymphovascular invasion, and tumor size. Level of Evidence Level 3.
otorhinolaryngology